Drugs / Indium-111-DOTA-Girentuximab-IRDye800CW
Indium-111-DOTA-Girentuximab-IRDye800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02497599 | Jun 2015 → Dec 2021 | renal cell carcinoma | Radboud University Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indium-111-DOTA-Girentuximab-IRDye800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02497599 ↗ |
| Modality | Protein / enzyme biologic | “Indium-111-DOTA-girentuximab-IRDye800CW is a perfect dual-labeled antibody” NCT02497599 ↗ |
| Route | Intravenous | “single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW” NCT02497599 ↗ |